We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Powdered Milk Reduces Gout Flares

By HospiMedica International staff writers
Posted on 09 Feb 2012
A new study suggests that daily consumption of enriched skim milk powder (SMP) could help prevent gout flares.

Researchers at the University of Auckland (New Zealand) conducted a proof-of-concept clinical trial to test the hypothesis that daily intake of SMP enriched with G600 and glycomacropeptide (GMP) can prevent gout flares. More...
The study involved 120 patients with recurrent gout flares who were randomized to one of three arms: lactose powder control, SMP control, and SMP enriched with GMP and G600. The lactose control, skim milk control, and enriched skim milk treatments all were administered as daily vanilla-flavored shakes. The primary end point was change in the frequency of gout flares using a daily flare diary measured monthly for three months.

The results showed that the frequency of gout flares reduced in all three groups over the study period, compared with baseline, with a significantly greater reduction in gout flares in the SMP enriched with GMP and G600 group. Following treatment with SMP enriched with GMP and G600 over the three-month period, greater improvements were also observed in pain and fractional excretion of uric acid, with trends to greater improvement in tender joint count. Similar adverse event rates and discontinuation rates were observed between the three groups. The study was published early online on January 4, 2012, in Annals of the Rheumatic Diseases.

“The specific fractions glycomacropeptide and G600 milk-fat extract, used to enrich skim milk powder, have been shown to exert anti-inflammatory effects in a murine model,” concluded lead author Nicola Dalbeth, MD, and colleagues of the department of molecular medicine. “These agents may have reduced gout flares through inhibition of the inflammatory response to monosodium urate crystals present within the joint.”

Gout (also known as podagra when it involves the big toe), is usually characterized by recurrent attacks of acute inflammatory arthritis. It is caused by elevated levels of uric acid in the blood, which crystallize, and the crystals deposited in joints, tendons, and surrounding tissues. Gout affects approximately 1%-2% of the Western population at some point in their lives, and the frequency is increasing in recent decades, probably due to increasing risk factors in the population, such as metabolic syndrome, longer life expectancy, and changes in diet.

Related Links:
University of Auckland



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Dual Chamber Warming Cabinet
D-Series
New
Powered Surgical Stapler
ECHELON 3000 Stapler
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.